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Abstract 
Over a decade after its start, Human Protein Atlas (HPA) has been 
developed as a universal database for human proteome. HPA has used 
both commercially designed and intra-designed antibodies for protein 
detection but both types should pass several validation tests like 
Western blot, immunohistochemistry, protein array and immunofluo-
rescence. However, importance of data reliability requires more sensi-
tive techniques to confirm specificity of antibodies to avoid any false 
data in HPA. Immunoprecipitation by help of magnetic beads (IP) 
coupled with Orbitrap Mass Spectrometry (MS) can be used as an 
antibody validation method with its incredible sensitivity and high 
capacity for different biological samples. In this study, it has been 
tried to test Orbitrap Mass Spectrometry and optimize a protocol for 
its future application as a validation method in HPA. 
Four proteins ATP5B, DDX1, IL18 and KRT7 with high expression 
(according to RNA data and IHC staining) and high reliability score 
for their antibodies and four pancreatic markers, GPR44, StradB, 
TMEM100 and SerpinB10 were selected to be detected in lysates 
from the cell lines, SIHA, RH-30, BEWO and HACAT respectively 
(for each cell line one safe and one pancreatic marker). Protein lysates 
prepared by RIPA buffer were used for Immunoprecipitation and pu-
rified samples were run on SDS gel, stained with Coomassie blue and 
several bands were selected to be cut and prepared for MS run by in-
gel digestion method. Peptides were run in Orbitrap Mass Spectrome-
try for detection. 
In total  three samples out of seven were detected as correct targets 
(one ATP5B, and two for KRT7), two samples with high molecular 
weight were detected as myosin which is a common contamination in 
proteomic lab and two bands belonging to GPR44 and TMEM100 
failed in detection  due to incorrect gel cutting. 
In total, HPA antibodies were successful in detection of target pro-
teins when gel bands were cut at correct molecular weight, but their 
mono-specificity should be further investigated since KRT7 came 
below contaminations. For a potential use of orbitrap MS as an anti-
body validation test, it is required to use clean facility, to preincubate 
dynabeads with antibody, to cut the gel at expected molecular weight 
for target protein and finally to filter out common contaminants in 
MS analysis to facilitate target protein detection. 
Key words: Antibody Validation, Immunoprecipitation, Magnetic 
Beads, Orbitrap Mass Spectrometry 
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1. Introduction 
Protein expression profiling from human samples is a valuable asset 
for assessment of individual health status. In the post-sequencing era, 
one of the most challenging topics for scientists is to unravel proteo-
mic content of human body, as a primary step to more precise protein 
expression profiling of individual cells. The whole Human genome 
sequencing project resulted in 20,364 genes, and this large number of 
genes can be translated into at least ~ 25000 protein products (Flicek 
et al., 2011). In reality, a much higher number of proteins is expected 
due to RNA splicing, post translational modification, protein degrada-
tion and last but not least the actual genetic variety among individuals 
( (Uhlén et al.a, 2005), (Uhlen et al.b, 2005)). Human Protein Atlas 
(HPA) is a comprehensive protein database in which a substantial 
number of human proteins have been mapped in normal tissues, can-
cer tissues and different human cell lines (Pontén et al., 2009). This 
project was first initiated by successfully mapping all protein prod-
ucts of the human chromosome 21 genes in 2003 (Agaton et al., 
2003).  HPA project has been extended gradually through these years 
to an inclusive database of nearly all known human proteins’ expres-
sion patterns, subcellular localization and transcript expression in 
human tissues and cell lines ( (Berglund et al., 2008), (Pontén et al., 
2009)).  
To map target proteins, the practical strategy is to generate polyclonal 
affinity-purified antibody against a very unique fragment of 100 to 
150 amino acids long of target antigen. These fragments are called 
protein epitope signature tags (PrESTs), which are templates for syn-
thetic peptides used for immunization in rabbits ( (Uhlén et al.a, 
2005), (Uhlen et al.b, 2005)).  
1.1. Antibody Validation in HPA 
Antibodies have to be validated through several steps to be able to use 
them for proteomic studies, and these methods are listed as following: 
1.1.1. Western blot 
Each antibody is used for Western blot against whole protein extract 
in two human cell lines RT-4, and U-251 MG, human plasma, liver 
and tonsil tissues. Usually a single band of correct molecular weight 
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is considered as the best result but multiple bands detection can be 
due to unknown splice variants or different post translational modifi-
cations rather than cross-reactivity ( (Uhlen et al.b, 2005), 
(www.proteinatlas.org)) 
1.1.2. Immunohistochemistry 
Each antibody is used to stain a tissue micro array (TMA) especially 
designed with duplicates or triplicates samples of 46 normal and 20 
cancer human tissues and 66 normal human cell lines and later coun-
ter stained by hematoxylin-eosin to visualize cellular compartments. 
Staining pattern is compared to available literature to validate im-
munohistochemistry ( (Kononen et al., 1998), 
(www.proteinatlas.org)). 
1.1.3. Protein Array  
384 different PrESTs are spotted on a glass slide divided into 14 
subarrays enabling simultaneous analysis of 14 different antibodies. 
Primary antibody and fluorescently labeled antibody are added and 
signal intensity for each spot is measured as an indication of antibody 
mono-specificity ( (Nilsson et al., 2005), (www.proteinatlas.org)). 
1.1.4. Immunofluorescence 
Each antibody has been tested for immunofluorescent staining of 
eleven types of human cells and localizing target protein within the 
cell. To facilitate protein visualization in cell, its nucleus, microtu-
bules and endoplasmic reticulum are stained by different fluorophores 
than of target protein. Subcellular position of target protein is com-
pared to available literature and eventually antibody is validated ( 
(Barbe et al., 2007), (www.proteinatlas.org u.d.)).These validation 
methods resulted in dismissal of a substantial number of generated 
antibodies due to failure in validation tests and the rest of them are 
scored as highly to lowly reliable antibodies (Uhlén et al.a, 2005). 
Since HPA plays an important role in research and diagnostics further 
validation of antibodies by siRNA technique or Mass Spectrometry 
can be of great advantage in particular for novel proteins with limited 
literature about them or proteins with many paralogues or orthologues 
which are quite tricky for antibody development. 
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1.2. Mass Spectrometry 
Mass spectrometry receives increasing popularity in proteomics as 
method of choice and it has been welcomed by researchers in this 
area for its incredible sensitivity for identification, characterization or 
quantitation of proteins in sophisticated biological samples. Many 
different mass spectrometry instruments have been launched and one 
of the latest versions is Orbitrap Mass Analyzer in which ions derived 
from the sample orbit by an electrostatic force around a central elec-
trode while centrifugal force of another electrode (encapsulating the 
central electrode) influences them. Ions’ oscillations frequencies are 
measured by a detector and m/z ratio of ions can be read with high 
accuracy. Method of choice for peptide identification is usually bot-
tom-up procedure in which purified sample is digested in order to 
obtain smaller peptides, Orbitrap instrument is able to detect peptide 
of 1ppm concentration accurately. In the Figure 1, Orbitrap main 
parts have been pictured very simply. In principle, Orbitrap Mass 
Analyzer consists of two electrodes, one electrode looks like a barrel 
ensheathing a cylinder shape inner electrode.  The outer electrode is 
split into two halves by an insulating layer of ceramic and provides an 
empty space for injected ions to orbit around the inner electrode, and 
by help of Fourier transform for each ion’s frequency of oscillation, 
its respective mass to charge ratio can be measured (Scigelova et al., 
2006). 
 
Figure 1:Schematic picture of orbitrap MS. Three main parts are shown; (a) inner 
electrode, (b ) outer electrode , and (c) isulator layer of ceramic dividing outer electrode 
into two halves , injected ions move in speiral patterns around inner electrode ( 
(Scigelova et al., 2006) with official permission from Thermofisher company) 
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1.3. Biomarkers to test Mass Spectrometry 
To test the Orbitrap Mass Spectrometry method several proteins were 
chosen. They were selected from HPA database based on their rele-
vantly good expression in corresponding cell lines (based on RNA 
concentration). These proteins can be categorized into two groups, 
one group containing safe markers with assured high expression in 
one specific cell line including ATP5B, DDX1, KRT7 and IL18. The 
other group consists of pancreatic proteins with apparently high and 
specific expression in the same cell line as safe marker; this group of 
markers includes GPR44, StradB, TMEM100 and SerpinB10. A brief 
description for each marker presented below. 
1.3.1. ATP5B 
This marker attributes to subunit β from Adenosine triphosphate syn-
thase (ATP synthase), a house keeping gene and the main intracellu-
lar energy producer located in mitochondria.  ATP synthase is com-
posed of two major entities; F˳ and F1. F˳ location is inside the inner 
membrane of mitochondria and consists of several subunits and β 
subunit is a major subunit for F˳ entity characterized as a 56.6 kD 
peptide ( (Jonckheere et al., 2012) (www.ensembl.org)). 
1.3.2. DDX1 
Dead (Asp, Glu, Ala, Asp) box helicase1 is a member of RNA hel-
icase family acting by unwinding RNA-RNA or RNA-DNA helices 
(Kitajima et al., 1994). As a RNA helicase, it has much to do with 
virus replication within cells, there are a several reports showing its 
role in increasing cells susceptibility to different viruses like HIV or 
JCV (Sunden et al., 2007). It has been reported that in retinoblastoma 
and neuroblastoma, cells have very high expression of it and it has 
been proposed as a potential prognostic marker for early stages of 
primary breast cancer , it has been characterized as ̴  82 kD protein ( 
(George et al., 1997), (Germain et al., 2011)).  
1.3.3. KRT7 
Keratin 7 has been classified as a simple type II Keratin filament ex-
pressed quite extensively in different types of epithelial cells from 
simple one layered cells to more stratified epithelial cell e.g. in stom-
ach. It has been characterized as a 55 kD protein with high similarity 
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to Keratin 8 ( (Smith et al., 2002), (Porter et al., 2003)). Its function is 
still quite unknown but it appears to be quite replaceable according to 
knockout mouse models although its absence might slightly affect 
urothelium of bladder (Sandilands et al., 2013). 
1.3.4. IL18 
Interleukin 18, a 22 kD protein classified as a member of IL-1 super-
family, is a cytokine with prominent role in regulation of both innate 
and acquired immune responses.  Its expression is reported in a wide 
range of type of cells but its seems that its mRNA  needs an especial 
machinery which could be found in immune system cells like B cells, 
T cells and Kupffer cells ( (Biet et al., 2000), (Matsui et al., 2003)). 
Several important functions have been reported for it like maturation 
of NK and T cell or cytokine production (Biet et al., 2000). 
1.3.5. GPR44 
G protein-coupled 44 was discovered quite recently. It is a 43 kD 
surface marker expressed particularly on Th2cells in human but can 
be found on other immune cell types e.g. eosinophils. Studies have 
shown that it has a prominent role in activation and chemotaxis of 
Th2cells in humans and its abundance increases in response to aller-
gens ( (Vinall et al., 2007), (Pettipher, 2008)). 
1.3.6. StradB 
STE20-related kinase adaptor beta was first discovered in a genomic 
region highly associated to Amyotrophic lateral sclerosis (ALS) 
(Hadano et al., 2001). This 47 kD kinase seems to be an isoform of 
more common pseudokinase and can act as an activator for AMP-
activated protein kinase (AMPK) ( (Boudeau et al., 2003), (Hawley et 
al., 2003)). It has been shown that STRADB10 presence has protec-
tive effect for cells against apoptosis by interacting with an inhibitor 
of apoptosis called XIAP (Sanna et al., 2002). 
1.3.7. TMEM100 
Transmembrane100 protein has been recently discovered and this 14 
kD protein is believed to be crucial for normal embryonic vascular 
development (Somekawa et al., 2012). Knockout mice embryos of 
TMEM100 die indicating its imperative role for healthy early stage 
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development. Embryos show deficiencies in arte-rial endothelium and 
vascular system morphogenesis (Somekawa et al., 2012). Study of its 
expression profile in human and mouse show its mRNA presence in 
only enteric neurons of gastrointestinal tract and also in mouse neu-
ronal cell bodies and fibers in the brain and basal ganglia root 
(Eisenman et al., 2013). 
1.3.8. SerpinB10 
Serine protease inhibitor B10 or Bomapin belongs to the SerpinB10 
superfamily, a large family of protease inhibitors found in nearly all 
organisms and its main function is to inhibit thrombin and trypsin 
within cells (Law et al., 2006). There are 35 Serpin genes in human 
genome and all of them have at least one structure in common, a mo-
bile reactive center loop (RCL) supported by a β sheet structure. Bo-
mapin (a 45kD protein) has quite restricted expression in human body 
and can be found in bone marrow, and in leukoctes of patients with 
myeloid leukemia (Przygodzka et al., 2010). 
1.4. Aims of Study 
In this study the primary goal was to optimize Orbitrap Mass Spec-
trometry potential to become part of routine antibody validation pro-
cedure in Human Protein Atlas. Immunoprecipitation was chosen as 
method of choice for protein purification for Mass Spectrometry run. 
The second aim was to check efficiency of detection for some pan-
creatic markers expression in specific cell lines. 
2. Methods and Materials 
2.1. Cell culture 
Four different human cell lines were used. Their maintenance condi-
tions and harvesting method are described below. 
2.1.1. HACAT 
HACAT cells (derived from human keratinocytes) were grown in 
sterile Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) sup-
plemented with 10% Heat inactivated(h.i.) Fetal Bovine Serum 
(FBS), 1% Penicillin and 2mM L-Glutamine at 37ºC and 5% CO2. 
13 
 
Cell medium was changed every 2- 3 days and, cells were split 1:7 
every three days. 
2.1.2. RH-30 
RH-30 cells (derived from human rhabdomyosin sarcoma) were 
grown in sterile RPMI-1640 medium supplemented with 10% (h.i.) 
FBS, 1% Penicillin, and 2mM L-Glutamine at 37ºC and 5% CO2. Cell 
culture medium was changed every two days and cells were split 1:6 
every three days. 
2.1.3. BEWO 
BEWO cells (derived from human placenta, choriocarcinoma) were 
grown in sterile Nutrient Mixture F-12 Ham medium (Sigma) sup-
plemented with 10% (h.i.) FBS, 1% Penicillin, 2mM L-Glutamine 
and 1.5 g/L NaHCO3 at 37ºC and 5% CO2. Cell culture medium was 
changed every other day and cells were split 1:2 every 3-4 days. 
2.1.4. SIHA 
SIHA cells (derived from cervix carcinoma, squamous cells) were 
grown in Minimum Essential Medium (Sigma) supplemented with 
10% (h.i.) FBS, 1% Penicillin, 2mM L-Glutamine, 1 mM Sodium 
Pyruvate, 0.1 mM non-essential amino acids (Life technologies), and 
1.5 g/L NaHCO3 at 37ºC and 5% CO2. Cell culture medium was 
changed every other day and cells were split 1:6 every three days. 
2.2. Cell split and harvesting 
To split each plates, cell culture medium was aspirated and cells were 
washed with 5 ml of sterile phosphate buffer (PBS). After PBS re-
moval, 3 ml of Trypsin- EDTA was added and the flask was incubat-
ed at 37º C for 5 minutes. Trypsin- EDTA was aspirated; this step 
was repeated again for HACAT and SIHA cells. 4 ml of fresh cell 
culture medium was added to detached cells and the cells were trans-
ferred to new plates and fresh cell culture medium was added up to 10 
ml. Cells were harvested when they were 70 % confluent by washing 
them in sterile PBS, addition of 3 ml of PBS and scraping the flask by 
a plastic cell scraper, this step was repeated again. Cells were centri-
fuged at 1500 x g for 10 minutes. Supernatant was removed and the 
cell pellet was kept in a -70º C freezer for future use. 
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2.3. Safe Marker selection 
All candidate markers were selected for detection in specific cell line 
based on strong RNA expression evidence in the corresponding cell 
line, supportive immunohistochemistry and Western blot data in Hu-
man Protein Atlas (http://www.proteinatlas.org/). 
2.4. Protein isolation by RIPA buffer 
Cell culture medium was aspirated and cells were washed by PBS, 
after PBS removal fresh PBS was added to harvest the cells. Cells 
were mechanically harvested by a plastic cell scraper and cell suspen-
sion was centrifuged at 1500 x g for 10 min, PBS was aspirated and 
cells were frozen for protein lysate preparation. RIPA buffer was pre-
pared by addition of 1ml of RIPA (Sigma, R0278), 10 µl of Protease 
Inhibitor Cocktail and 1.5 µl of Benzonase (CalBioCHEM) were add-
ed to a 2ml Eppendorf tube. One cell pellet (containing ~ 10- 15 x 10
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cells) was thawed  on ice and based on pellet size 200 to 400 µl of 
RIPA buffer was added to it. The cell suspension was pipetted up and 
down several times, transferred to an Eppendorf tube and put on a 
shaking table for at least 20 minutes. The tube was centrifuged at 20 x 
10
3
 g for 20 minutes.  Supernatant was transferred to a new Eppen-
dorf tube. 
2.5. SDS-PAGE 
Protein lysates prepared by RIPA were measured by Qubit 2,0 fluo-
rometer (Invitrogen, life technologies) and based on the lysate con-
centration an appropriate amount of lysates was used for sample 
preparation to have 20 µg of protein lysate per well. Lysate was 
mixed with 87% glycerol (to the final concentration of 20% of glyc-
erol) and 4 µl of 5x Red. Samples were heated on a heating block at 
95 ºC for 5 minutes and subsequently cooled down by leaving it on 
room temperature for few minutes. Samples were loaded on an 18-
well comb 10-20 % Criterion™ SDS-PAGE gradient gel (Biorad) 
with running buffer of Tris /Glycine/ SDS (Biorad). For each set of 
samples at least one well was loaded with 5 µl of Page Ruler Marker, 
and 20 µl of prepared sample was loaded in the well. Gel tank (Bio-
rad, Mini Trans Blot Electrophoresis Transfer Cell) was put in a 4 °C 
cold room and it was run at 130 V for 90 minutes. 
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2.6. Western blot 
After gel run, gel was released from its frame and was equilibrated in 
Transfer buffer (Tris /Glycine (Biorad)) for 15 minutes. All the Fiber 
pads, paper pads and the cassette for assembly were equilibrated in 
transfer buffer as well. Proteins were transferred to the membrane 
(Biorad Mini Trans Blot Electrophoresis Transfer Cell) at 75 V for 45 
minutes. Membrane was blocked with 5% skim milk in Tris based 
saline with 0.5% Tween 20 (0.5% TBST) on a rock ´n´ roll shaker for 
1 hour, then block buffer was removed and 2-3 ml of diluted antibody 
was added to the membrane and the mixture was incubated for 1 hour 
on the rock ´n´ roll shaker. Membrane was washed with 0.05% TBST 
four times for 5 minutes and incubated with 5 ml of HRP-conjugated 
secondary antibody on the rock ´n´ roll shaker for 1 hour. Membrane 
was washed with 0.05% TBST four times for 5 minutes and incubated 
in the development solution (Super Signal West Dura-kit) for 5 
minutes and possible bands were detected by Biorad molecular im-
ager Chemidoc XRS device and Quantity One software. To check 
protein concentration of selected markers in cell lines each marker 
concentration was checked in all four cell lines lysates, the list of 
used antibodies is shown in Table 1. 
2.7. Immunoprecipitation 
1-2 µg of antibody was added to each protein lysate prepared by RI-
PA buffer and incubated on a rotating table in the cold room for 3-4 
hours. Lysate- antibody mix was added to 50 µl of Dynabeads protein 
A coupled (Invitrogen), incubated on rotating table in the cold room 
for 1 hour, and washed as instructed in the Dynabeads protocol (Cat. 
no.100.06D, Invitrogen). Samples were collected from beads by elut-
ing in 20 µl of elution buffer and stored at -70ºC freezer before run-
ning in comassie gel. 
List of antibodies used for each proteins are shown in Table 1. 
 
Table 1: list of antibodies for safe markers and pancreatic proteins 
 
Safe Marker Antibody Pancreatic Pro-
tein 
Antibody 
ATP5B HPA001520 GPR44 HPA014259 
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DDX1 HPA034502 StradB HPA 026549 
KRT7 HPA007272 TMEM100 Origine-2D3 
(mouse-
monoclonal) 
IL18  Epitomics – 
EP523Y 
(rabbit-
monoclonal) 
SerpinB10 HPA015480 
*All HPA antibodies are from rabbit. 
 
2.8. Coomassie blue staining 
Purified samples (20 µl) were prepared for SDS-PAGE as mentioned 
above and gel was run at 130 V for 90 minutes. Gel was released 
from the frame, washed with 100 ml of miliQ water 3 times for 5 
minutes. 20 ml of Simply Blue Safe Stain was added to the gel and 
put on the gently shaking table in room temperature for 1 hour. Gel 
was washed with water four times for 1 hour (Figure 3). Some bands 
were cut from the gel and stored in the fridge. 
 
2.9. Mass Spectrometry sample preparation 
Gel bands were cut into smaller pieces, incubated with 150 µl of 25 
mM of NH4HCO3 for 5 minutes. After removal of supernatant the gel 
pieces were incubated with 150 µl of Acetonitrile (ACN) for 5 
minutes. Destaining step was repeated twice. Gel pieces were dried in 
SpeedVac® for 10-15 minutes. Dried gel was covered with 10 mM 
dithiothreitol (DTT), incubated at 50º C for 1 hour, and supernatant 
was discarded. 55mM Iodoacetamide was added to gel pieces to cov-
er them and they were incubated in darkness for 1 hour. Then the gel 
pieces were washed with 150 µl of 25 mM of NH4HCO3 for 5 
minutes, supernatant removed and gel bands were incubated with 150 
µl of Acetonitrile (ACN) for 5 minutes. Gel pieces were dried in 
SpeedVac® for 10-15 minutes. Proteins were partially digested by a 
solution of trypsin and Ammonium Hydrogencarbonate (12 ng/µl of 
trypsin in 25 mM of NH4HCO3) and incubated at room temperature 
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for 1 hour. 25 mM of NH4HCO3 was added to gel bands to cover 
them and the gel pieces were incubated at 37ºC overnight. Superna-
tants were collected the day after, to gel bands a solution of 60% 
ACN and 5 % formic acid was added. The mixture was incubated for 
5 minutes and supernatant was pooled with previous fractions. Sam-
ples were dried in SpeedVac®. The rest of preparation for running 
samples in MS was done by MS facility personnel. 
3. Results 
All markers were tested by Western blot in the four cell lines to check 
their expression level. Ideally, highest expression should be in the cell 
line that marker was going to be purified later with only single band 
of correct size. In figure 2 KRT7 Westren blot  image is shown as an 
example. 
 
 
 
Figure 2: Western blot image of KRT7 with HPA007272 antibody. On the left side of 
the image molecular marker is shown (250, 130, 100, 70, 55, 35, 25, 15, 10 kD), KRT7 in 
SIHA, BEWO, RH-30 and HACAT cells (left to right) was tested and it showed two 
bands for SIHA , one strong band for BEWO, no band in RH-30 and one band for 
HACAT 
 
Purified samples were stained by Coomassie blue and several bands 
were cut. Due to technical limitation seven samples belonging to 5 
markers out of 8 were selected to be analyzed in MS run. For some of 
the markers more than one band were present in the gel which were 
cut and sent for Mass Spectrometry analysis. In Figure 3 a Coomassie 
gel image is shown.  
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Figure 3: Coomassie gel image of purified lysates after Immunoprecipitation. Three 
lanes of marker were loaded (first, last and the fifth lanes (250, 130, 100, 70, 55, 35, 25, 
15, 10 kD)). After staining, spots with high concentration of proteins turned blue. Mass 
Spectrometry samples were cut based on their bands position in Western blot. 
 
Names and positions of analysed bands are summerized in Table 2 
below. Gel bands for markers were cut according to Western blot 
result. 
Table 2: List of selected gel bands for MS analysis. Selected gel bands for MS run are 
listed below, their marker type shown in first column, approximate size of each band is 
shown in second column and results of MS run are shown in last column. For markers 
more than one band was present in gel and all bands were cut and they are shown in 
table with a number after marker’s name. 
Sample Molecular 
weight of 
marker 
Approximate 
size of gel band 
(kD) 
Mass 
Spectrometry 
result 
ATP5B 56 50-55 ATP5B 
GPR44 43.3 50-55 ND 
KRT7(1) 55 ̴ 47-50 KRT7 
KRT7(2) 55 ̴ 50-53 KRT7 
KRT7(3) 55 ≤250 ND 
STRADB10 47 ≤250 ND 
TMEM ̴ 14.4 45 ND 
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Based on the MS results three of the samples were sucessfully 
detected, bands cut for ATP5B and KRT7 were correctly detected as 
their corresponding proteins, yet one heavy band from KRT7 located 
around 250 kD was not detected as KRT7. This  heavy band was 
present in other marker’s lanes and it was cut for StradB10 as well.  
The heavy bands were detected as Myosin by MS instead of their 
corresponding marker.  It should be mentioned for first Kerain7 band 
located around 47 kD the first few hits in MS run were common con-
taminants such as actins, tubulins and Keratin8 while KRT7 scored 
lower than contaminations. 
GPR44 and TMEM bands were cut according to Western blot results 
and observation of a faint band yet common contaminents  were 
detected by MS. 
4. Discussion 
In this study, we aimed to test Orbitrap Mass spectrometry as a poten-
tial antibody validation method in Human Protein Atlas.  Four pro-
teins were selected as safe markers based on their high expression in a 
specific cell line and robust Western blot results according to HPA, 
these markers are positive controls and should be detected in a Mass 
Spectrometry run. Four pancreatic markers with no certain infor-
mation on their antibodies’ specificity were selected to be checked. 
All samples were tested by Western blot in all cell lines to check their 
expression and purified by Immunoprecipitation before running in 
orbitrap Mass Spectrometry.  
One sample from ATP5B and two from KRT 7 were detected in Mass 
Spectrometry and for both safe markers HPA antibodies were used 
for pull-down. HPA001520 (ATP5B antibody) was able to pull it 
down with accuracy and ATP5B came as the first detected protein in 
Mass Spectrometry results. This can prove that HPA001520 antibody 
as a mono-specific and reliable antibody which can pull down its tar-
get in complex biological combination (whole SIHA cells lysate) with 
great accuracy. 
KRT7 samples contained impurities that made its identification re-
sults less solid than ATP5B but it should be noted that Keratins are 
quite difficult proteins to be pulled down due to their unique charac-
teristics; this family is one of the most common proteins in human 
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samples (Hannan et al., 2009). Moreover, their presence as contami-
nation in purified samples is a recurrent problem in proteomic labs ( 
(Hodge et al., 2013) (Mellacheruvu et al., 2013)). Keratins have vari-
ous types, yet they show amazing similarity in structure (Porter et al., 
2003) which complicates antibody development for this protein fami-
ly. Not surprisingly, there is evidence that keratin 18 antibody (clone 
CY-90 Sigma Aldrich) shows strong affinity for Keratin 13 as well 
(Fulzele et al., 2012). In this study, KRT7 was chosen for two rea-
sons, first, to check Fulzele’s study results which are critical for anti-
body development and validation, for Keratins or similar proteins and 
to test HPA antibody reliability. Second, Keratins are biomarkers of 
epithelial cells and KRT7 is a unique biomarker for BEWO cell line 
(Hannan et al., 2009) which makes it an interesting protein to study.  
HPA007272 antibody was successful in pulling down KRT7 in BE-
WO cell lysate for both gel bands yet KRT7 was not the top protein in 
the Mass Spectrometry results. Actin and other types of Keratins (like 
KRT8) came before KRT7 indicating that there might be unspecific 
binding of these proteins. Since KRT7 should be present in BEWO 
cells in high concentration ( (Hannan et al., 2009), 
(www.proteinatlas.org)), its low abundance should not be the problem 
for detection.  
However, considering the persistent presence of different Keratins in 
most biological samples as contamination and the fact that Keratins 
are amazingly similar in structure, HPA007272 antibody is quite suc-
cessful in detection of KRT7 in BEWO cell lysate which is quite so-
phisticated sample with high concentration of different keratins in it 
(www.proteinatlas.org). It is worth mentioning that the first KRT7 
band (located at ̴ 47 kD) was not exactly at the right molecular weight 
and this could contribute to detection of lower concentration of KRT7 
and identification of contaminants instead of target protein. But extra 
band presence after Coomassie staining, and results of Western blot 
in SIHA protein lysate made the other band an interesting sample to 
study. 
The other analyzed bands belonged to GPR44 (Mw 43.3) and 
TMEM100 (Mw 14.4) (www.ensembl.org). Location of their gel 
bands and real molecular weight were not in line with each other and 
consequently none of them were detected in Mass Spectrometry run. 
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The reason for cutting bands in position other than their real molecu-
lar weight was the results of Western blot. Western blot is one of the 
validation methods in HPA and these two proteins showed bands in 
positions totally different than expected molecular weight. Bands 
were cut according to Western blot leading to detection of common 
contaminants in low concentrations in Mass Spectrometry. The two 
remaining samples were heavy molecular weight bands which were 
showing up in almost all lanes and after Mass Spectrometry analysis; 
they were detected as myosin contamination. Myosin contamination 
similar to Keratins, is reported as one of the most recurrent and com-
mon contaminants in different proteomics labs (Mellacheruvu et al., 
2013).  
Immunoprecipitation by magnetic beads was selected as protein puri-
fication method and magnetic beads have showed superiority to con-
ventional sepharose beads by taking up less non-specific nuclear pro-
teins, however they are not perfectly specific for antibody-protein 
complex and can take up proteins associated with cell structure or 
motility such as Actin, Myosin and Tubulin ( (Trinkle-Mulcahy et al., 
2008) (Mellacheruvu et al., 2013)).  
Human protein Atlas (HPA) has extremely important responsibility of 
authentic information provision for scientists, researchers and clini-
cians and to accomplish this role, it has to set up a thorough antibody 
validation process to ensure accuracy of the data. In this study, we 
tried to address this need by means of orbitrap Mass Spectrometry 
and checking HPA antibodies efficiency. HPA have been mostly re-
lied on immunoassays like Immunohistochemistry or Western blot for 
antibody validation which without any doubts have certain  merits  ( 
(Matos et al., 2010), (Bordeaux et al., 2010)), yet they have their own 
flaws and one important one is low sensitivity for distinguishing be-
tween markers with similar molecular weight or staining pattern ( 
(Hoofnagle et al., 2009) (Becker et al., 2012)). Mass Spectrometry 
receives more attention as method of choice in high-throughput pro-
teomic labs due to its sensitivity and high capacity for simultaneous 
detection of several targets in complex samples. Orbitrap Mass Spec-
trometry can be a useful asset in any lab with its incredible sensitivity 
(capable of protein detection in ppm concentration). In this study, 
Orbitrap MS was able to identify right targets when gel bands were 
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cut at correct molecular weight and revealed samples ‘contaminants 
with incredible precision. However, it cannot be denied that its appli-
cation in HPA lab needs more trials to prepare an efficient protocol 
for it. To improve future Immunoprecipitation and Orbitrap Mass 
Spectrometry some suggestion could be applied: 
It is necessary to use laminar flow hood to reduce risk of entering 
contaminations from lab environment. Lab technician responsible for 
Immunoprecipitation should use long sleeved clean gloves. 
The gel should always be cut where the expected protein should be 
present regardless of Western blot results or Coomassie blue staining 
results. 
To avoid unspecific binding of proteins to dynabeads, incubate anti-
body with magnetic beads to cover beads surface with antibody prior 
to addition of protein lysate, to hide all potential interaction sites for 
non-target proteins on the beads. 
To skip detection of contaminants in Mass Spectrometry common 
contaminants can be filtered out ( (Trinkle-Mulcahy et al., 2008), 
(Mellacheruvu et al., 2013)) 
In conclusion, the total success rate of orbitrap Mass Spectrometry 
run was about 43% and three samples out seven were successfully 
detected. HPA antibodies were successful in detection of correctly cut 
bands of safe markers yet their mono-specificity and affinity for just 
one target protein could be further tested with Mass Spectrometry 
since it clearly detect  co-purified proteins and contaminations. Pan-
creatic markers failed in Mass Spectrometry due to incorrect gel cut-
ting and consequently no data is available on their antibody’s effi-
ciency yet modification of Immunoprecipitation protocol and Mass 
Spectrometry sample analysis could be of great help. 
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